Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2579.35% is 100% below its 4-year average of 13162831.27%, near the low end of its 4-year range (-2579.35%–52655100.00%).
57.44% below its 12-month average of -1638.32%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2025-12-31): -1638.32%.
EBITDA MARGIN
-2579.35%
EBITDA MARGIN AVG TTM
-1638.32%
EBITDA MARGIN AVG 3Y
17550607.78%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-57.44%
CURRENT VS 3Y AVG
-100.01%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Gelteq Limited Ordinary Shares
Market Cap
$5.05M
EBITDA Margin
-2579.35%
TTM Avg
-1638.32%
3Y Avg
17550607.78%
5Y Avg
N/A
Market Cap
$5.06M
EBITDA Margin
-4837.99%
TTM Avg
-4449.42%
3Y Avg
-4104.15%
5Y Avg
-4023.55%
Market Cap
$5.01M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
Market Cap
$5.17M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.24M
EBITDA Margin
-123.71%
TTM Avg
-161.92%
3Y Avg
-255.04%
5Y Avg
-225.97%
Market Cap
$5.26M
EBITDA Margin
-271.50%
TTM Avg
-294.22%
3Y Avg
-453.19%
5Y Avg
-366.18%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.05M | -2579.35% | -1638.32% | 17550607.78% | N/A |
| Imunon, Inc. (IMNN)vs › | $5.06M | -4837.99% | -4449.42% | -4104.15% | -4023.55% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -8.85% | 9.13% | 18.32% | 18.32% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.17M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.24M | -123.71% | -161.92% | -255.04% | -225.97% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.26M | -271.50% | -294.22% | -453.19% | -366.18% |
| CalciMedica, Inc. (CALC)vs › | $4.82M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.77M | -1670.57% | -1446.66% | -2067.25% | -1679.39% |
Gross Margin
100.0%
EBITDA Margin
-2579.3%
Operating Margin
-3317.7%
Net Margin
-4011.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -1638.32% |
| 2025-09-30 | -1638.32% |
| 2023-06-30 | 52655100.00% |
| 2022-06-30 | -498.28% |
